



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

June 10, 2021

Garo Armen  
Executive Chairman  
Protogenic Therapeutics, Inc.  
149 Fifth Avenue  
New York, New York 10010

**Re: Protogenic Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed June 4, 2021**  
**File No. 333-256790**

Dear Mr. Armen:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Nicholas Lamparski at 202-551-4695 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Trade & Services

cc: Dean M. Colucci